Home/Filings/4/0001213900-22-027791
4//SEC Filing

Mattes Glenn R. 4

Accession 0001213900-22-027791

CIK 0001733413other

Filed

May 16, 8:00 PM ET

Accepted

May 17, 9:51 PM ET

Size

5.8 KB

Accession

0001213900-22-027791

Insider Transaction Report

Form 4
Period: 2022-05-16
Mattes Glenn R.
DirectorPresident and CEO
Transactions
  • Purchase

    Common Stock

    2022-05-16$4.78/sh+16,000$76,48036,000 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    7,000
Footnotes (1)
  • [F1]The reported shares were purchased in the open market in multiple transactions at prices ranging from $4.32 to $4.95. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Documents

1 file

Issuer

TFF Pharmaceuticals, Inc.

CIK 0001733413

Entity typeother

Related Parties

1
  • filerCIK 0001568678

Filing Metadata

Form type
4
Filed
May 16, 8:00 PM ET
Accepted
May 17, 9:51 PM ET
Size
5.8 KB